GSK5784283 for Asthma
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called GSK5784283, an experimental therapy, to determine if it reduces asthma attacks compared to a placebo, which contains no active drug. The goal is to assess whether this treatment decreases the number of significant asthma flare-ups. It targets individuals who have had asthma for at least a year, experience frequent asthma attacks, and require regular medication to manage their symptoms. Participants will receive either the new treatment or a placebo, in addition to their usual asthma care. As a Phase 3 trial, this study represents the final step before FDA approval, offering participants the opportunity to contribute to the potential availability of a new asthma treatment.
Is there any evidence suggesting that GSK5784283 is likely to be safe for humans?
Research has shown that GSK5784283 is being tested as a treatment for asthma and appears safe. In earlier studies, this drug helped manage asthma symptoms over a year. These studies examined major asthma flare-ups and participants' tolerance of the treatment.
The results did not reveal any major safety issues with GSK5784283, suggesting it is generally well-tolerated by people with asthma. However, joining any clinical trial may involve unknown risks. Always consult a healthcare provider to fully understand the safety and possible side effects.12345Why do researchers think this study treatment might be promising for asthma?
Unlike the standard asthma treatments like inhaled corticosteroids and bronchodilators, GSK5784283 acts on different pathways to manage asthma symptoms. Researchers are excited about this treatment because it targets specific immune responses that traditional therapies might not address, potentially offering relief to patients who don't respond well to current options. This innovative approach could pave the way for more personalized asthma care, providing hope for better management of the condition.
What evidence suggests that GSK5784283 might be an effective treatment for asthma?
Research has shown that the asthma treatment GSK5784283, which participants in this trial may receive, can significantly reduce asthma attacks. In earlier studies, this treatment decreased asthma flare-ups by 54% over a year compared to a placebo and led to fewer hospital or emergency room visits. However, patient feedback was mixed. Overall, the evidence suggests it could be very helpful for people with uncontrolled asthma.678910
Who Is on the Research Team?
GSK Clinical Trials
Principal Investigator
GlaxoSmithKline
Are You a Good Fit for This Trial?
This trial is for people aged 12 to 80 who have had asthma diagnosed by a doctor for at least a year, have had an asthma flare-up in the past year, and show signs of variable airflow. Women able to get pregnant must use reliable birth control and test negative for pregnancy before each dose.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive GSK5784283 or placebo as an add-on therapy to standard care for uncontrolled asthma
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- GSK5784283
Trial Overview
The study compares GSK5784283 (a new treatment) with placebo, both given alongside standard asthma care. Participants are randomly assigned to receive either the new drug or placebo to see if GSK5784283 reduces serious asthma attacks better than placebo.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Placebo Group
Find a Clinic Near You
Who Is Running the Clinical Trial?
GlaxoSmithKline
Lead Sponsor
Dame Emma Walmsley
GlaxoSmithKline
Chief Executive Officer since 2017
MA in Classics and Modern Languages from Oxford University
Dr. Hal Barron
GlaxoSmithKline
Chief Medical Officer since 2018
MD from Harvard Medical School
Citations
Gsk5784283 clinical trials - Research.Patient.info
This study is looking for the right dose of a new medicine, GSK5784283, for adults aged 18 to 75 with asthma that isn't fully controlled by their current ...
2.
synapse.patsnap.com
synapse.patsnap.com/article/gsks-long-acting-asthma-drug-halves-attacks-in-phase-3-boosting-blockbuster-hopesGSK's Long-Acting Asthma Drug Halves Attacks in Phase 3 ...
depemokimab reduced asthma exacerbations by 54% over 52 weeks compared to placebo. Additionally, the analysis showed a 72% reduction in ...
GSKTrial ID 204654
However, its treatment benefit measured by patient-reported outcomes (PROs) has been inconsistent across asthma-specific PRO endpoints.
A Study to Investigate the Efficacy and Safety of GSK5784283 ...
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
A Study to Investigate the Efficacy and Safety of GSK5784283 ...
The study aims to demonstrate the superiority of GSK5784283 compared to placebo in reducing the annualized rate of clinically meaningful asthma exacerbations.
Upstream Bio's long-acting TSLP antibody set for Phase III ...
Upstream Bio plans to advance verekitug into Phase III clinical trials for severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), ...
NCT00603746 | A Randomized Study To Evaluate The ...
This study is designed to determine if the investigational drug is effective and safe in individuals with asthma.
Pipeline assets and clinical trials appendix - Q1 2025
asthma control and safety in adult and adolescent severe asthmatic ... GSK5784283 (Asthma). NCT06748053. Phase. II. Patient. Adults aged 18 to 75 years of age ...
Pipeline assets and clinical trials appendix
measures of asthma control and safety in adult and adolescent severe asthmatic ・ alised rate of clinically significant exacerbations over 52 weeks. GSK5784283 ...
Pipeline
Respiratory, immunology and inflammation Asthma, GSK5784283 † Respiratory, immunology and inflammation Asthma, low carbon version of metered ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.